Acorda Therapeutics (ACOR) Reports Q3 EPS of 28c
Tweet
Share
E-mailGet Alerts ACOR Hot Sheet
Price: $0.66 --0%
Financial Fact:
Interest and amortization of debt discount expense: -4.4M
Today's EPS Names:
BTTX, VAXX, ELYS, More
Financial Fact:
Interest and amortization of debt discount expense: -4.4M
Today's EPS Names:
BTTX, VAXX, ELYS, More
Join SI Premium – FREE
Acorda Therapeutics (NASDAQ: ACOR) reported Q3 EPS of $0.28, may not compare to the analyst estimate of $0.05. Revenue for the quarter came in at $106 million versus the consensus estimate of $94.7 million.
It raised full year 2014 guidance for AMPYRA net revenue from $328-$335 million to $345-$350 million
For earnings history and earnings-related data on Acorda Therapeutics (ACOR) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Walmart (WMT) PT Lowered to $130 at UBS on Investment Narrative's Competing Dynamics
- Flowers Foods (FLO) Misses Q2 EPS by 3c; Offers Guidance
- BMO starts chip stocks coverage: Here are its preferred picks
Create E-mail Alert Related Categories
Earnings, GuidanceRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
